ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI

Read more at globenewswire.com